Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related ...

People who have tried other methods to lose weight have found results from obesity drugs that ‘feel like magic.’ ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep medicine.

Ascletis's news arrives shortly after Eli Lilly reported favourable Phase III weight loss data for its oral GLP-1RA, ...

A new study from Rutgers University links higher body dissatisfaction, BMI, and maladaptive weight loss behaviors with ...

Aditya Khemka, Fund Manager at InCred Asset Management, remains cautious about Indian companies looking to manufacture GLP-1 ...

Ascletis is taking a low and slow approach to oral GLP-1 dose titration in a phase 2a test after getting a look at clinical ...

CompanyOverview|NYSE:LLY] The world’s largest pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), is back in the green ...

Weight loss drugs can cause side effects including nausea, vomiting, diarrhoea, haemorrhoids and constipation, which can ...

A large population-based study found that GLP-1 receptor agonists (GLP-1RAs) and SGLT2 inhibitors (SGLT2is), two classes of ...

The first step of setting up a new device starts with cleaning up your old phone. If you’re planning on trading in your old ...